Clinical trials
Completed Phase 1 Urinary Bladder Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
135 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 5 |
| 2001 | 5 |
| 2002 | 1 |
| 2003 | 4 |
| 2004 | 5 |
| 2005 | 2 |
| 2006 | 6 |
| 2007 | 5 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 6 |
| 2012 | 6 |
| 2013 | 7 |
| 2014 | 5 |
| 2015 | 8 |
| 2016 | 10 |
| 2017 | 6 |
| 2018 | 7 |
| 2019 | 8 |
| 2020 | 7 |
| 2021 | 5 |
| 2022 | 5 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 135 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 10 |
| Memorial Sloan Kettering Cancer Center | 6 |
| M.D. Anderson Cancer Center | 4 |
| The University of Texas Health Science Center at San Antonio | 3 |
| Bayer | 2 |
| Celgene | 2 |
| Celldex Therapeutics | 2 |
| Eli Lilly and Company | 2 |
| H. Lee Moffitt Cancer Center and Research Institute | 2 |
| Incyte Corporation | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Urinary Bladder Neoplasms | 135 |
| Carcinoma, Non-Small-Cell Lung | 45 |
| Breast Neoplasms | 41 |
| Prostatic Neoplasms | 35 |
| Ovarian Neoplasms | 32 |
| Carcinoma, Renal Cell | 31 |
| Colorectal Neoplasms | 31 |
| Lung Neoplasms | 30 |
| Pancreatic Neoplasms | 29 |
| Neoplasms | 28 |
Trials
Showing 1 to 25 of 135. Each trial links to its page on Pharma Observatory.
35 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.